Bridgebio Pharma

Q2 FY2026 EarningsQ2 FY26 delivered a strong top-line beat with total revenue of $243.7M vs. $219.7M expected (+10.9%), fueled by Attruby™ net product sales reaching $222.4M. However, GAAP EPS of -$0.78 missed the -$0.59 consensus due to a significant ramp in SG&A and R&D expenses to support commercial scale-up and late-stage clinical submissions. Despite the bottom-line miss, a post-quarter $933.9M preferred stock financing dramatically improves the liquidity profile ahead of several high-value PDUFA dates in FY27.